Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Plain-language summary
This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone (DRUG): tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details